05 Oct 2026, 08:41 IST
Divi's Laboratories Limited
Motilal Oswal Financial Services Ltd. (MOFSL) · BUY · target ₹10,800
A 'Velocity Idea' says Divi's is positioned for peptide/CDMO opportunities and tariff clarity, projecting 21% earnings CAGR over FY26-28, with SL ₹8,870.
From MOStMarketOutlook05102026, written by Motilal Oswal Financial Services Ltd. (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal Financial Services Ltd. (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.